Cardiovascular (CV) mortality is now the most common cause of death in men with prostate cancer, even exceeding prostate cancer mortality.1 Several studies have shown androgen deprivation therapy, which is still the cornerstone of treatment for men with hormone-dependent prostate cancer, is associated with an increased risk of cardiovascular disease (CVD).2,3 However, recent evidence suggests it is now time to consider which androgen deprivation therapy (ADT) modality is most suitable for patients with cardiovascular risk factors.4